Sidoti Estimates Cibus’ Q1 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Equities research analysts at Sidoti reduced their Q1 2026 earnings per share estimates for shares of Cibus in a report issued on Wednesday, May 13th. Sidoti analyst A. Hantman now expects that the company will earn ($0.36) per share for the quarter, down from their previous estimate of ($0.32). The consensus estimate for Cibus’ current full-year earnings is ($1.13) per share. Sidoti also issued estimates for Cibus’ Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.28) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.14) EPS.

Cibus (NASDAQ:CBUS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million. Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. Jefferies Financial Group increased their price objective on Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cibus has a consensus rating of “Hold” and an average price target of $9.00.

Cibus Stock Down 3.1%

CBUS stock opened at $1.41 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.72 and a current ratio of 0.72. The company has a market capitalization of $107.65 million, a price-to-earnings ratio of -0.47 and a beta of 1.66. Cibus has a fifty-two week low of $1.09 and a fifty-two week high of $4.19. The stock has a fifty day moving average of $2.12 and a 200-day moving average of $1.97.

Institutional Trading of Cibus

Several institutional investors and hedge funds have recently modified their holdings of CBUS. Rockland Trust Co. purchased a new stake in shares of Cibus in the 3rd quarter valued at about $26,000. PACK Private Wealth LLC purchased a new stake in shares of Cibus in the 4th quarter valued at about $27,000. Dimensional Fund Advisors LP purchased a new stake in shares of Cibus in the 1st quarter valued at about $33,000. Qube Research & Technologies Ltd purchased a new stake in shares of Cibus in the 2nd quarter valued at about $39,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Cibus in the 3rd quarter valued at about $62,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Key Cibus News

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Cibus beat revenue expectations in Q1, reporting $1.68 million versus the $1.61 million consensus, and its loss per share was slightly better than the Zacks estimate. Article: Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management also provided a business update and said Cibus has runway into late Q1 2027, which may ease near-term financing concerns, though it also pushed the U.S. rice launch to 2029. Article: Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029
• Negative Sentiment: Cibus reported Q1 EPS of -$0.33, missing the consensus estimate of -$0.27, reinforcing concerns that profitability remains distant. Article: Cibus earnings report
• Negative Sentiment: Sidoti lowered earnings estimates across multiple periods, including FY2026 to -$1.45 from -$1.18 and FY2027 to -$1.14 from -$0.88, signaling a more cautious outlook from analysts. Article: Sidoti estimate revisions for Cibus

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.